Doxazosin: An Update of its Clinical Pharmacology and Therapeutic Applications in Hypertension and Benign Prostatic Hyperplasia

Drugs

Volumn 49, Issue 2, 1995, Pages 295-320

  Fulton, Bret ^a   Wagstaff, Antona J ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBOHYDRATE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NADOLOL; NIFEDIPINE; NITRENDIPINE; PRAZOSIN; TERAZOSIN; VASOACTIVE AGENT;

BLADDER FUNCTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FIBRINOLYSIS; GLUCOSE METABOLISM; HEADACHE; HEART LEFT VENTRICLE MASS; HEMODYNAMICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALAISE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; RESPIRATORY TRACT DISEASE; REVIEW; SOMNOLENCE; SYNCOPE; THROMBOCYTE; URINE FLOW RATE; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VERTIGO;

CARBOHYDRATES; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DOSAGE FORMS; DOXAZOSIN; DRUG EVALUATION; HEART VENTRICLE; HEMODYNAMICS; HUMAN; HYPERTENSION; LIPIDS; MALE; PROSTATIC HYPERPLASIA;

EID: 0028869716     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199549020-00011     Document Type: Article

References (144)

1. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension
2. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension
3. Concentrationeffect relationships and individual responses to doxazosin in essential hypertension
4. Clinical pharmacotherapeutics of doxazosin
5. Alfluzosin: a reveiw of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
6. The role of alpha-adrenergic blockers in the treatment of prostatic hypertrophy
7. Benign prostatic hyperplasia. Current pharmacological treatment
8. Rationale for α-blockade in BPH therapy
9. Binding and functional properties of doxazosin in the human prostate adenoma and canine brain
10. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension
11. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: A one-year, double-blind study in 228 hypertensive patients
12. Serum lipid changes in a one year, multicenter double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension
13. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized double-blind trial: the alpha beta Canada study
14. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study
15. Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension
16. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension — results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects
17. Treatment of arterial hypertension in non-insulin-dependent diabetic patients: comparison of doxazosin and enalapril
18. Placebo-controlled trial of doxazosin in management of patients with hypertension and hypercholesterolaemia
19. A multicenter long-term trial comparing doxazosin and nitrendipine in the treatment of mild to moderate essential hypertension associated with hypercholesterolemia
20. Effects of doxazosin on blood pressure and serum lipids in hypertensive patients [in Japanese]
21. Daae LNW Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers
22. A long-term double blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension
23. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins
24. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension
25. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension
26. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension
27. A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension
28. Treatment of Mild Hypertension Study. Final results
29. Factors influencing the lipid response to selective alpha 1-inhibition
30. Effect of doxazosin on cholesterol synthesis in cell culture
31. Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse
32. Influence of doxazosin on lipid transport in rats and hamsters
33. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia
34. Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension
35. Metabolic disturbances and antihypertensive therapy
36. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism
37. Effects of selective alfal and betal-adreno-receptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity
38. Doxazosin improves insulin sensitivity in hypertensive patients
39. Lowered levels of serum insulin, glucose, and cholesterol in hypertensive patients during treatment with doxazosin
40. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension: comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus
41. Alpha-1 blocker doxazosin improves insulin sensitivity in diabetic hypertensive patients [abstract]
42. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients
43. Usefulness of doxazosin in the treatment of hypertensive patients with diabetes mellitus [in Japanese]
44. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise
45. Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function
46. Vascular pressor responses in treated and untreated essential hypertension
47. Antihypertensive effect of doxazosin and atenolol in short-term and long-term doubleblind comparison
48. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension
49. Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension
50. Comparative effects of enalapril and doxazosin in hypertensive patients with coronary artery disease
51. 2 and endurance capacity in well-trained athletic hypertensive men
52. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers
53. Blood pressure and heart rate response to repeated smoking before and after betablockade and selective alpha 1 inhibition
54. Antihypertensive therapy in the geriatric patient: II. Areview of the alpha 1-adrenergic blocking agents
55. Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein
56. Regression of increased left ventricular mass by antihypertensives
57. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin
58. Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study
59. Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension
60. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature
61. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
62. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol
63. Selective alphal inhibition with doxazosin in hypertensive smokers and nonsmokers: haemodynamic and metabolic effects
64. The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study
65. Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study
66. Acute renal effects of doxazosin in man
67. 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension
68. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin
69. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure
70. The effects of food on the oral bioavailability of doxazosin in hypertensive subjects
71. Single-dose and steadystate pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects
72. Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension
73. The pharmacokinetics of doxazosin in patients with hypertension and renal impairment
74. Clinical pharmacological studies with doxazosin
75. Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline α-adrenoceptor agonists in normotensive volunteers
76. 1-adrenoceptor antagonist: pharmacokinetics and concentration effect relationships in man
77. The pharmacokinetics of doxazosin in elderly normotensives
78. Clinical pharmacology of doxazosin in patients with essential hypertension
79. The metabolism and kinetics of doxazosin in man, mouse, rat and dog
80. Apharmacodynamic and pharmacokinetic assessment of a new α-adrenergic antagonist, doxazosin (UK33274) in normotensive subjects
81. Doxazosin: concentration-effect relationships
82. Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure
83. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension
84. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin
85. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension
86. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate hypertension
87. The antihypertensive effects of doxazosin: a clinical overview
88. Combination of nifedipine and doxazosin in essential hypertension
89. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine
90. Alpha-adrenoceptor blockade and Ca++ blockade: a new combination for the treatment of hypertension [abstract]
91. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers
92. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial
93. Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients
94. A clinical pharmacological assessment of doxazosin and enalapril in combination
95. Synergism between alphal-blockade and angiotensin converting enzyme inhibition in essential hypertension
96. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy
97. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension
98. Doxazosin in resistant hypertension
99. Doxazosin: alternative antihypertensive treatment [letter]
100. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus
101. Effects of alphal-adrenergic blockade doxazosin on blood pressure, glucose and lipid metabolism in hypertensive patients with diabetes mellitus [abstract]
102. Doxazosin in the management of hypertensive diabetes — a cautionary note (?)
103. Effects of captopril, nifedipine and doxazosin on insulin sensitivity in non-insulin dependent diabetic hypertensive patients [abstract]
104. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD
105. Doxazosin in the treatment of hypertension in patients with chronic obstructive pulmonary disease
106. An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency
107. An evaluation of the efficacy and safety of doxazosin in hypertension associated with renal dysfunction
108. Effect of doxazosin on blood pressure and renal haemodynamics of hypertensive patients with renal failure
109. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency
110. A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication
111. Coronary risk prediction in adults (the Framingham heart study)
112. Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience
113. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction
114. Doxazosin treatment in patients with prostatic obstruction — a doubleblind placebo-controlled study
115. A multicenter sixteen-week double blind placebo-controlled dose-response study using doxazosin tablets for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension [abstract]
116. A sixteen week, double-blind, placebo-controlled, dose-titration study using doxazosin tablets for the treatment of benign prostatic hyperplasia in normotensive males [abstract]
117. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyerplasia — a double-blind placebo-controlled study
118. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies
119. Doxazosin: a new alpha 1-adrenergic antagonist
120. Doxazosin: antihypertensive effect in hypertensive vs. normotensive BPH patients with BPH [abstract]
121. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society
122. 1989 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting